Cathepsin K - A classical bone biomarker in cardiovascular disease: The heart is not alone anymore

Atherosclerosis

Volumn 228, Issue 1, 2013, Pages 36-37

  Vassalle, Cristina ^a   Iervasi, Giorgio ^a  

^a INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

Author keywords

Atherosclerosis; Cathepsin K; Coronary artery disease

Indexed keywords

CARBOXYPEPTIDASE C; CATHEPSIN K;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; EXTRACELLULAR MATRIX; HUMAN; NOTE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

CATHEPSIN K; CORONARY ARTERY DISEASE; FEMALE; HUMANS; MALE;

EID: 84876786964     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2013.01.042     Document Type: Note

References (21)

1. Lutgens S.P., Cleutjens K.B., Daemen M.J., et al. Cathepsin cysteine proteases in cardiovascular disease. FASEB J 2007, 21:3029-3041.
2. Costa A.G., Cusano N.E., Silva B.C., et al. CatK: its skeletal actions and role as a therapeutic target in osteoporosis. Nat Rev Rheumatol 2011, 7:447-456.
3. Cheng X.W., Shi G.P., Kuzuya M., et al. Role for cysteine protease cathepsins in heart disease: focus on biology and mechanisms with clinical implication. Circulation 2012, 125:1551-1562.
4. Brömme D., Lecaille F. CatK inhibitors for osteoporosis and potential off-target effects. Expert Opin Investig Drugs 2009, 18:585-600.
5. Cheng X.W., Kikuchi R., Ishiia H., et al. Circulating CatK as a potential novel biomarker of coronary artery disease. Atherosclerosis 2013, 228:211-216.
6. Sukhova G.K., Shi G.P., Simon D.I., et al. Expression of the elastolytic cathepsins S and K in human atheroma and regulation of their production in smooth muscle cells. J Clin Invest 1998, 102:576-583.
7. Hofnagel O., Robenek H. CatK: boon or bale for atherosclerotic plaque stability?. Cardiovasc Res 2009, 81:242-243.
8. Lutgens E., Lutgens S.P., Faber B.C., et al. Disruption of the CatK gene reduces atherosclerosis progression and induces plaque fibrosis but accelerates macrophage foam cell formation. Circulation 2006, 113:98-107.
9. Cheng X.W., Kuzuya M., Sasaki, et al. Increased expression of elastolytic cysteine proteases, cathepsins S and K, in the neointima of balloon-injured rat carotid arteries. Am J Pathol 2004, 164:243-251.
10. Platt M.O., Ankeny R.F., Shi G.P., et al. Expression of cathepsin K is regulated by shear stress in cultured endothelial cells and is increased in endothelium in human atherosclerosis. Am J Physiol Heart Circ Physiol 2007, 292:H1479-H1486.
11. Chatzizisis Y.S., Baker A.B., Sukhova G.K., et al. Augmented expression and activity of extracellular matrix-degrading enzymes in regions of low endothelial shear stress colocalize with coronary atheromata with thin fibrous caps in pigs. Circulation 2011, 123:621-630.
12. Helske S., Syväranta S., Lindstedt K.A., et al. Increased expression of elastolytic cathepsins S, K, and V and their inhibitor cystatin C in stenotic aortic valves. Arterioscler Thromb Vasc Biol 2006, 26:1791-1798.
13. Balachandran K., Sucosky P., Jo H., Yoganathan A.P. Elevated cyclic stretch alters matrix remodeling in aortic valve cusps: implications for degenerative aortic valve disease. Am J Physiol Heart Circ Physiol 2009, 296:H756-H764.
14. Asagiri M., Hirai T., Kunigami T., et al. CatK-dependent toll-like receptor 9 signaling revealed in experimental arthritis. Science 2008, 319:624-627.
15. Lindstedt L., Lee M., Oörni K., Brömme D., Kovanen P.T. Cathepsins F and S block HDL3-induced cholesterol efflux from macrophage foam cells. Biochem Biophys Res Commun 2003, 312:1019-1024.
16. Funicello M., Novelli M., Ragni M., et al. CatK null mice show reduced adiposity during the rapid accumulation of fat stores. PLoS One 2007, 2:e683.
17. Yang M., Sun J., Zhang T., et al. Deficiency and inhibition of CatK reduce body weight gain and increase glucose metabolism in mice. Arterioscler Thromb Vasc Biol 2008, 28:2202-2208.
18. Hua Y., Zhang Y., Dolence J., Shi G.P., Ren J., Nair S. Cathepsin K knockout mitigates high-fat diet-induced cardiac hypertrophy and contractile dysfunction. Diabetes 2013, 62:498-509.
19. Dadu R.T., Nambi V., Ballantyne C.M. Developing and assessing cardiovascular biomarkers. Transl Res 2012, 159:265-276.
20. Singh V., Martinezclark P., Pascual M., Shaw E.S., O'Neill W.W. Cardiac biomarkers - the old and the new: a review. Coron Artery Dis 2010, 21:244-256.
21. Lim V., Clarke B.L. New therapeutic targets for osteoporosis: beyond denosumab. Maturitas 2012, 73:269-272.